Author, as appears in the article.: Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; Gudiño-Cabrera G; Ureña-Guerrero ME; Verdaguer E; Folch J; Auladell C; Camins A

Department: Bioquímica i Biotecnologia

URV's Author/s: FOLCH LOPEZ, JAUME

Keywords: Clinical studies Dementia Neuroinflammation Novel therapies Synapses

Abstract: The increases in population ageing and growth are leading to a boosting in the number of people living with dementia, Alzheimer's disease (AD) being the most common cause. In spite of decades of intensive research, no cure for AD has been found yet. However, some treatments that may change disease progression and help control symptoms have been proposed. Beyond the classical hypotheses of AD etiopathogenesis, i.e., amyloid beta peptide (Aβ) accumulation and tau hyperphosphorylation, a trend in attributing a key role to other molecular mechanisms is prompting the study of different therapeutic targets. Hence, drugs designed to modulate inflammation, insulin resistance, synapses, neurogenesis, cardiovascular factors and dysbiosis are shaping a new horizon in AD treatment. Within this frame, an increase in the number of candidate drugs for disease modification treatments is expected, as well as a focus on potential combinatory multidrug strategies.The present review summarizes the latest advances in drugs targeting Aβ and tau as major contributors to AD pathophysiology. In addition, it introduces the most important drugs in clinical studies targeting alternative mechanisms thought to be involved in AD's neurodegenerative process.

Thematic Areas: Biochemistry & molecular biology Biochemistry, genetics and molecular biology (miscellaneous) Biodiversidade Biotecnología Cell biology Ciência de alimentos Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Economia Educação física Enfermagem Farmacia General biochemistry,genetics and molecular biology General immunology and microbiology Immunology and microbiology (miscellaneous) Interdisciplinar Medicina i Medicina ii Medicina iii Medicine (miscellaneous) Química

licence for use: https://creativecommons.org/licenses/by/3.0/es/

Author's mail: jaume.folch@urv.cat

Author identifier: 0000-0002-5051-8858

Record's date: 2022-06-18

Papper version: info:eu-repo/semantics/publishedVersion

Link to the original source: https://www.imrpress.com/journal/FBL/27/5/10.31083/j.fbl2705146

Papper original source: Frontiers In Bioscience-Landmark. 27 (5): 146-

APA: Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; Gudiño-Cabrera G; Ureña-Guerrero ME; Verdaguer E; Folch J; A (2022). Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease. Frontiers In Bioscience-Landmark, 27(5), 146-. DOI: 10.31083/j.fbl2705146

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Article's DOI: 10.31083/j.fbl2705146

Entity: Universitat Rovira i Virgili

Journal publication year: 2022

Publication Type: Journal Publications